ATE491696T1 - Neue 2,4-diaminothiazol-5-onderivate - Google Patents
Neue 2,4-diaminothiazol-5-onderivateInfo
- Publication number
- ATE491696T1 ATE491696T1 AT05759691T AT05759691T ATE491696T1 AT E491696 T1 ATE491696 T1 AT E491696T1 AT 05759691 T AT05759691 T AT 05759691T AT 05759691 T AT05759691 T AT 05759691T AT E491696 T1 ATE491696 T1 AT E491696T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- derivatives
- novel
- treatment
- disclosed
- Prior art date
Links
- BLPGWIBMZNEFCR-UHFFFAOYSA-N 2,4-diamino-2h-1,3-thiazol-5-one Chemical class NC1SC(=O)C(N)=N1 BLPGWIBMZNEFCR-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- QHHHLHCCVDMOJI-UHFFFAOYSA-N 1,3-thiazol-4-amine Chemical class NC1=CSC=N1 QHHHLHCCVDMOJI-UHFFFAOYSA-N 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 108091007914 CDKs Proteins 0.000 abstract 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000037841 lung tumor Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023958 prostate neoplasm Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58818404P | 2004-07-15 | 2004-07-15 | |
| PCT/EP2005/007342 WO2006005508A1 (en) | 2004-07-15 | 2005-07-07 | Novel 2,4-diaminothiazol-5-one derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE491696T1 true ATE491696T1 (de) | 2011-01-15 |
Family
ID=35115799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05759691T ATE491696T1 (de) | 2004-07-15 | 2005-07-07 | Neue 2,4-diaminothiazol-5-onderivate |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7423053B2 (de) |
| EP (1) | EP1771424B1 (de) |
| JP (1) | JP2008505950A (de) |
| KR (1) | KR100908591B1 (de) |
| CN (1) | CN1976910B (de) |
| AT (1) | ATE491696T1 (de) |
| AU (1) | AU2005261954A1 (de) |
| BR (1) | BRPI0511826A (de) |
| CA (1) | CA2573603A1 (de) |
| DE (1) | DE602005025357D1 (de) |
| MX (1) | MX2007000425A (de) |
| RU (1) | RU2395501C2 (de) |
| WO (1) | WO2006005508A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| WO2018089902A1 (en) * | 2016-11-13 | 2018-05-17 | Apogee Biotechnology Corporation | Diaminothiazole compounds, compositions and methods of use |
| CN114306255B (zh) * | 2021-12-30 | 2023-05-23 | 北京鑫开元医药科技有限公司 | 一种甲基酮类衍生物药物制剂及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2728901B1 (fr) * | 1994-12-28 | 1997-03-28 | Sanofi Sa | Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| UA66810C2 (uk) * | 1997-10-27 | 2004-06-15 | Агорон Фармацевтикалз Інк. | Похідні 4-амінотіазолу та композиції на їх основі як інгібітори циклінозалежних кіназ |
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| KR20020027649A (ko) | 1999-09-15 | 2002-04-13 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 카이나제 억제제로서의 프테리딘온 |
| EP1235815A1 (de) | 1999-11-22 | 2002-09-04 | Warner-Lambert Company | Chinazoline und ihre verwendung als cyclin-dependent kinase enzym- inhibitoren |
| WO2001056567A1 (en) | 2000-02-04 | 2001-08-09 | Novo Nordisk A/S | 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors |
| BR0110302A (pt) | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
| HN2002000156A (es) * | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
| MXPA04000906A (es) | 2001-08-03 | 2004-11-22 | Novo Nordisk As | Nuevos derivados de 2,4-diaminotiazol. |
| BRPI0407456A (pt) * | 2003-02-12 | 2006-01-31 | Pfizer | Derivados antiproliferativos de 2-(sulfo-fenil)-aminotiazole e composições farmacêuticas, e métodos para o seu uso |
| CA2516234A1 (en) * | 2003-02-21 | 2004-09-02 | Pfizer Inc. | N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors |
| US7211576B2 (en) * | 2004-04-20 | 2007-05-01 | Hoffmann-La Roche Inc. | Diaminothiazoles |
-
2005
- 2005-06-29 US US11/170,636 patent/US7423053B2/en not_active Expired - Fee Related
- 2005-07-07 WO PCT/EP2005/007342 patent/WO2006005508A1/en not_active Ceased
- 2005-07-07 BR BRPI0511826-3A patent/BRPI0511826A/pt not_active IP Right Cessation
- 2005-07-07 CA CA002573603A patent/CA2573603A1/en not_active Abandoned
- 2005-07-07 DE DE602005025357T patent/DE602005025357D1/de not_active Expired - Lifetime
- 2005-07-07 CN CN2005800216787A patent/CN1976910B/zh not_active Expired - Fee Related
- 2005-07-07 JP JP2007520717A patent/JP2008505950A/ja active Pending
- 2005-07-07 EP EP05759691A patent/EP1771424B1/de not_active Expired - Lifetime
- 2005-07-07 KR KR1020077000842A patent/KR100908591B1/ko not_active Expired - Fee Related
- 2005-07-07 MX MX2007000425A patent/MX2007000425A/es active IP Right Grant
- 2005-07-07 RU RU2007105557/04A patent/RU2395501C2/ru not_active IP Right Cessation
- 2005-07-07 AT AT05759691T patent/ATE491696T1/de not_active IP Right Cessation
- 2005-07-07 AU AU2005261954A patent/AU2005261954A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007000425A (es) | 2007-03-07 |
| CA2573603A1 (en) | 2006-01-19 |
| BRPI0511826A (pt) | 2007-12-26 |
| US7423053B2 (en) | 2008-09-09 |
| AU2005261954A1 (en) | 2006-01-19 |
| RU2007105557A (ru) | 2008-08-20 |
| EP1771424B1 (de) | 2010-12-15 |
| CN1976910A (zh) | 2007-06-06 |
| RU2395501C2 (ru) | 2010-07-27 |
| KR100908591B1 (ko) | 2009-07-22 |
| KR20070020557A (ko) | 2007-02-21 |
| DE602005025357D1 (de) | 2011-01-27 |
| EP1771424A1 (de) | 2007-04-11 |
| CN1976910B (zh) | 2010-07-21 |
| JP2008505950A (ja) | 2008-02-28 |
| WO2006005508A1 (en) | 2006-01-19 |
| US20060014958A1 (en) | 2006-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002057261A3 (en) | Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase | |
| BRPI0511975A (pt) | pirazolopirimidinas | |
| BRPI0513836A (pt) | composto, métodos de tratar, controlar ou prevenir cáncer, uma doença associada com angiogênese indesejada, e uma doença ou distúrbio mediado por pde 4, e de reduzir ou inibir o nìvel ou a atividade de pde 4 em um paciente, e, composição farmacêutica | |
| ATE453636T1 (de) | Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren | |
| EE200200123A (et) | Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine | |
| EA201400111A1 (ru) | Ингибиторы mek и способы их применения | |
| TW200407326A (en) | Pyrimido compounds having antiproliferative activity | |
| WO2006081230A3 (en) | 3-(indazol-5-yl)-(1,2, 4) triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer | |
| NO20075849L (no) | Fremgangsmater og preparater til behandling eller forebygging av kreft | |
| PE20050523A1 (es) | Pirazoles como inhidores de factor de necrosis tumoral | |
| ATE343575T1 (de) | Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz | |
| TW200724543A (en) | Heterocyclic compounds and their uses as therapeutic agents | |
| TNSN05188A1 (en) | 4-aminopyrimidine-5-one | |
| PL1809288T3 (pl) | Zastosowanie pochodnych 1,4-bis-(3-aminoalkilo)piperazyny do leczenia chorób neurodegeneracyjnych | |
| TW200612929A (en) | Novel 2,6-diaminopyridine-3-one derivatives | |
| ATE435224T1 (de) | Neue piperidinsubstituierte diaminothiazole | |
| DE602005025357D1 (de) | Neue 2,4-diaminothiazol-5-onderivate | |
| ATE367825T1 (de) | Zusammensetzung und kit zur verwendung in der tumorbehandlung | |
| DE602004009097D1 (de) | 1.3.4-triaza-phenalen- und 1,3,4,6-tetraazaphenalen-derivative | |
| BRPI0815334A2 (pt) | derivados de pirazolo[3,4-d]-piramidina como agentes antiproliferativos | |
| WO2003080624A3 (en) | Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases | |
| DE60305520D1 (de) | 2" oxo-voruscharin und derivaten | |
| ATE432933T1 (de) | Flavopereirinderivate zur krebstherapie | |
| DE502004008294D1 (de) | Neue makrocyclen zur behandlung von krebserkrankungen | |
| UY27131A1 (es) | Diaminotiazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |